Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more

Specsavers launches special charity design

Specsavers has released two limited edition frames, designed in collaboration with Aboriginal artist and Gumatj leader Mr Peter Datjing Burarrwanga, to benefit the Fred Hollows Foundation’s work in Australia. Read more